JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

1.38 2.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.35

Max

1.3900000000000001

Galvenie mērījumi
By Trading Economics
Ienākumi	-51K -928K
EPS	-0.254
Darbinieki	2
EBITDA	-51K -928K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-6.5M 4.9M
Iepriekšējā atvēršanas cena	-0.84
Iepriekšējā slēgšanas cena	1.38

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 00:00 UTC

Galvenie ziņu notikumi

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026. g. 22. apr. 23:33 UTC

Peļņas

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026. g. 22. apr. 22:40 UTC

Peļņas

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026. g. 22. apr. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:11 UTC

Peļņas

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026. g. 22. apr. 21:01 UTC

Peļņas

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026. g. 22. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026. g. 22. apr. 23:16 UTC

Peļņas

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026. g. 22. apr. 23:15 UTC

Peļņas

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026. g. 22. apr. 22:52 UTC

Peļņas

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026. g. 22. apr. 22:51 UTC

Peļņas

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026. g. 22. apr. 22:29 UTC

Peļņas

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026. g. 22. apr. 22:27 UTC

Peļņas

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026. g. 22. apr. 22:06 UTC

Tirgus saruna

Peļņas

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026. g. 22. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:47 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:37 UTC

Peļņas

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026. g. 22. apr. 21:34 UTC

Peļņas

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026. g. 22. apr. 21:29 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:20 UTC

Tirgus saruna

Peļņas

Tesla Expands Manufacturing to Chips -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.